Drug shortage
Dexmedetomidine Hydrochloride Injection · Mylan Institutional, a Viatris Company
FDA drug shortage · Current · updated Oct 5, 2026
Key facts
| Generic name | Dexmedetomidine Hydrochloride Injection |
|---|---|
| Company | Mylan Institutional, a Viatris Company |
| Presentation | Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10) |
| Dosage form | Injection |
| Status | Current |
| Therapeutic category | Anesthesia |
| Package NDCs | 67457-925-10 |
| First posted | Apr 10, 2020 |
| Last updated | Oct 5, 2026 |
At a glance
- 1–9 Package NDCs affected
- 100–999 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: